|
1
|
Zhang Y, Wei X and Pan T: Simultaneous
surgical treatment of non-small cell lung cancer and off-pump
coronary artery bypass grafting. Zhongguo Fei Ai Za Zhi.
12:332–336. 2009.(In Chinese). PubMed/NCBI
|
|
2
|
Sheffield BS, Fulton R, Kalloger SE, Milne
K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E,
et al: Investigation of PD-L1 biomarker testing methods for PD-1
axis inhibition in non-squamous non-small cell lung cancer. J
Histochem Cytochem. 64:587–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sorber L, Zwaenepoel K, Deschoolmeester V,
van Schil PE, van Meerbeeck J, Lardon F, Rolfo C and Pauwels P:
Circulating cell-free nucleic acids and platelets as a liquid
biopsy in the provision of personalized therapy for lung cancer
patients. Lung Cancer. 107:100–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Liu Y, Shao H and Zheng X:
Obesity paradox in lung cancer prognosis: Evolving biological
insights and clinical implications. J Thorac Oncol. 12:1478–1488.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Richeldi L, Collard HR and Jones MG:
Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raghu G, Brown KK, Collard HR, Cottin V,
Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, et
al: Efficacy of simtuzumab versus placebo in patients with
idiopathic pulmonary fibrosis: A randomised, double-blind,
controlled, phase 2 trial. Lancet Respir Med. 5:22–32. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raghu G, Wells AU, Nicholson AG, Richeldi
L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R and
Hansell DM: Effect of nintedanib in subgroups of idiopathic
pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care
Med. 195:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morrissey C, Corey E, Brown L, Coleman I,
Nguyen H, Schweizer M and Nelson P: Targeting the FGFR pathway in
androgen receptor negative castration resistant prostate cancer.
Cancer Res. 77:Abst 2076. 2017.doi:10.1158/1538-7445.AM2017-2076.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riihimäki M, Hemminki A, Fallah M, Thomsen
H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and
survival in lung cancer. Lung Cancer. 86:78–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martinez FJ, de Andrade JA, Anstrom KJ,
King TE Jr and Raghu G; Idiopathic Pulmonary Fibrosis Clinical
Research Network: Randomized trial of acetylcysteine in idiopathic
pulmonary fibrosis. N Engl J Med. 370:2093–2101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hutchinson J: Idiopathic pulmonary
fibrosis: Another step in understanding the burden of this disease.
Eur Respir J. 48:26–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang
DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification
of microRNA-214 as a negative regulator of colorectal cancer liver
metastasis by way of regulation of fibroblast growth factor
receptor 1 expression. Hepatology. 60:598–609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katoh M and Nakagama H: FGF receptors:
Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goyal L, Saha SK, Liu LY, Siravegna G,
Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V,
Kambadakone A, et al: Polyclonal secondary FGFR2 mutations drive
acquired resistance to FGFR inhibition in patients with FGFR2
fusion-positive cholangiocarcinoma. Cancer Discov. 7:252–263. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li D, Zhang H, Ma L, Han Y, Xu M, Wang Z,
Jiang H, Zhang W, Wang L and Pan Y: Associations between microRNA
binding site SNPs in FGFs and FGFRs and the risk of non-syndromic
orofacial cleft. Sci Rep. 6:310542016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soulitzis N, Karyotis I, Delakas D and
Spandidos DA: Expression analysis of peptide growth factors VEGF,
FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic
hyperplasia. Int J Oncol. 29:305–314. 2006.PubMed/NCBI
|
|
17
|
Siegfried JM, Farooqui M, Rothenberger NJ,
Dacic S and Stabile LP: Interaction between the estrogen receptor
and fibroblast growth factor receptor pathways in non-small cell
lung cancer. Oncotarget. 8:24063–24076. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Babina IS and Turner NC: Advances and
challenges in targeting FGFR signalling in cancer. Nat Rev Cancer.
17:318–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mori Y, Nakamura S, Kishimoto S, Kawakami
M, Suzuki S, Matsui T and Ishihara M: Preparation and
characterization of low-molecular-weight heparin/protamine
nanoparticles (LMW-H/P NPs) as FGF-2 carrier. Int J Nanomed.
5:147–155. 2010. View Article : Google Scholar
|
|
20
|
Hasday JD, Scheraga RG, Thompson C,
Tulapurkar M, Cowan MJ, Sun JF, Cai RM, Logun C, Todd NW, Shelhamer
J, et al: Heat-Shock accelerates human lung epithelial wound
healing by activating expression of fibroblast growth factor
(FGF)-1: Implications for idiopathic pulmonary fibrosis (IPF). Am J
Respir Crit Care Med. 193:A14612016.
|
